Drug Trial Radar · NCT06933329
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
73
Planned (sponsor's estimate)
Start
Jul 18, 2025
Primary completion
Aug 31, 2028
Study completion Feb 28, 2029
Sponsor
- Lead sponsor
- BicycleTx LimitedIndustry
- Sponsor type
- Industry
- First posted
- Apr 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a global, multicenter, open-label study that aims to assess the efficacy and safety of zelenectide pevedotin in participants with previously treated NECTIN4-amplified advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior line of systemic therapy in the advanced/metastatic setting (see inclusion criteria below). The study will comprise of 2 cohorts: Cohort A (non-squamous NSCLC) and Cohort B (squamous NSCLC).
Conditions
- Non-Small Cell Lung Cancer
Interventions
Zelenectide pevedotinDrug
Participants will receive zelenectide pevedotin on Days 1, and 8 of every 21-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) assessed by InvestigatorTime frame: Up to approximately 3 years
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Institut Curie
Paris, France
Complejo Hospitalario Universitario A Coruña
A Coruña, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.